Consequences of Delayed Diagnosis in Treatment of Retinoblastoma

Mohammad Faranoush1,2, MD; Amir Abbas Hedayati Asl1, MD; Azim Mehrvar1,3, MD; Narjes Mehrvar*1, MSc; Rokhsanef Zangooei1, MD; Ehsan Abadi1; Mardawig Alebouyeh1, MD; Maryam Tashvighi1,4, MD

1MAHAK Pediatric Cancer Treatment and Research Center; 2 Iran University of Medical Sciences; 3 Army Medical Sciences University, Tehran; 4 Azad University of Medical Sciences (Qom Branch), Qom, Iran

Received: Apr 08, 2014; Accepted: May 18, 2014; First Online Available: Jul 30, 2014

Abstract

Objective: One of the primary factors in managing patients with retinoblastoma is early diagnosis. The main idea of this study was to recognize the consequences of delay in diagnosis on therapy of the disease.

Methods: A retrospective review of all children with proven retinoblastoma, who had presented to MAHAK hospital in Tehran, from April 2007 to Dec 2011, was performed. Grouping of intraocular tumors was applied as A to E according to International Classification of Retinoblastoma.

Findings: There were 157 (91 boys) children eligible for study. The mean age was 1.21±0.11 years with average delay in diagnosis of 3.4±0.53 months. Classification of B group in both unilateral (93 patients) and bilateral tumors was the largest category. A significant relation (P=0.05) between delayed diagnosis time and tumor grouping was evident. The most frequent symptoms were leukocoria and strabismus. Age was significantly lower in the subgroup of bilateral tumors than in unilateral retinoblastomas (0.6±0.12 year vs 1.6±0.15 years). The diagnosis was delayed in subgroup of extra ocular retinoblastoma more than in intraocular tumors (8.7±2.9 months vs 2.9±0.52 months).

Conclusion: The authors recommend early referring of suspected cases to ophthalmologists and pediatric oncologists and to organize educational programs to publicize signs and symptoms of the disease such as leukocoria, strabismus and ocular inflammatory disorders through national media. In conclusion, early diagnosis of retinoblastoma can be the primary factor in managing the patients as the delay in diagnosis accounts for highly advanced disease and poor prognosis.

Key Words: Childhood Malignancy; Eye Tumor; Delayed Diagnosis; Retinoblastoma

Introduction

Retinoblastoma, a malignant intraocular tumor, is commonly detected by parents seeing general signs of this disease[1,2]. In spite of being a rare childhood cancer, it is a common primary ocular tumor in children[3,4], the incidence rate of retinoblastoma is approximately 1 in 15000 and 1 in 16600 live births in the United States and northern Europe respectively [5,6]. This malignancy is more frequent in Latin America, Africa and India[7,8].

During past 80 years, the curability rate has been dramatically increased to more than 90%[9,10]. The five years overall survival rate in retinoblastoma is greater than 90%[11-13]. Early diagnosis shortly after the detection of symptoms can improve survival rate[14]. The delay in clinical diagnosis depends on the medical culture of the country and awareness of the parents[14]. The
The estimated time interval between the first symptoms and clinical diagnosis can be a landmark of risk factor for altering survival rate in retinoblastoma, as the late diagnosis results in poor prognosis[14,15].

In order to investigate the consequences of delayed diagnosis in treatment of children with retinoblastoma, we conducted this study in MAHAK Pediatric Cancer Treatment and Research Center (MPCTRC), a referral childhood malignancy center in Tehran, Iran.

**Subjects and Methods**

We undertook a retrospective review of all children with retinoblastoma, who were admitted to MPCTRC from April 2007 to Dec 2011. Only patients with clinically confirmed tumor by pediatric ophthalmologist were included in the study. Information for each patient including sex, age at diagnosis, the clinical manifestations, date of first symptoms, date of diagnosis, date of initiation of therapy, laterality and stage of the tumor was recorded.

MPCTRC, being a large and well-known referral childhood malignancy center in the capital, receives children with retinoblastoma referred for chemotherapy from the whole country.

Based on the clinical examinations and according to International Classification of Retinoblastoma (ICRB), groupings were applied as A to E for intraocular retinoblastoma[16,17].

Data was analyzed by SPSS version 19. Comparison of mean values was performed using the non-parametric Mann-Whitney test for unpaired samples, and chi-squared for parametric variables. All P-values were two-sided and considered statistically significant when <0.05.

**Findings**

The inclusion criteria were met by 157 patients (n=91, 58% boys). The mean age was 1.21±0.11 years (median 1.0 years; interquartile range 0-2 years; range: 0 to 6 years). The mean interval between the first detection of symptoms and the clinical diagnosis was 3.4±0.53 months (median 1 month; interquartile range 5.7–88.7 days; range 0-36.5 months). A delay in the diagnosis of less than 5 months was found for 105 (66.9%) children, and 9 (5.7%) patients were diagnosed with retinoblastoma longer than 15 months after the first symptoms were recognized.

In 93 (59.2%) children, the tumor was unilateral. Intraocular tumor was found in 141 (89.8%) patients. Classification of D in children with bilateral tumor formed the largest group (n=40 eyes; 38.5%), followed by E (n=27 eyes; 26%), B (n=16 eyes; 15.4%), C (n=12 eyes; 11.5%) and finally by the A group (n=9 eyes; 8.6%). Children with unilateral tumor showed class D as the largest group (n=37 eyes; 45.1%), followed by E (n=28 eyes; 34.1%), C (n=9 eyes; 11.1%), B (n=7 eyes; 8.5%) and finally by the A group (n=1 eye; 1.2%). Chi-squared test showed the significant relation (P<0.05) between tumor grouping and delayed diagnosis in enrolled patients (median delay time: group A 1.2±0.7 months; group B 0.2±0.1 months; group C 1.5±0.6 months; group D 3.6±0.9 months; group E: 4.8 ±1.06 months).

Categorizing the whole enrolled patients by age into subgroups of 0-2 years, 2-4 years and more than 4 years showed that the diagnostic delay was significantly (P<0.05) the longest in the elder aged group of more than 4 year olds (7.6±3.8 months; median 11.5 days; interquartile range 4.5 days to 18.7 months; range 0-36.5 months) compared with the youngest age group 0-2 years (3.5±0.6 months; median 1.0 month; interquartile range 6.5 to 94 days; range 0-29.3 months) and the middle-aged group 2-4 years (2.1±0.53 months; median 1.0 month; interquartile range 5 to 65 days; range 0-14.13 months) (Fig. 1).

The most frequent symptoms were leukocoria in 106 (67.51%) children with a mean delay in the diagnosis of 3.4±0.58 months (median 1 month; interquartile range 7 to 88 days; range 0-29.3 months) (Fig. 2). Strabismus was the leading symptom for 33 (25.4%) children, in whom the mean diagnostic delay was 2.9±0.7 months (median 31 days; interquartile range 10 to 121 days; range 0-18 months). As shown in Fig 2, presence of poor vision and eye inflammation predicted a late diagnosis of the tumor.
The most frequent symptoms were leukocoria in 106 (67.51%) children with a mean delay in the diagnosis of 3.4±0.58 months (median 1 month; interquartile range 7 to 88 days; range 0-29.3 months) (Fig. 2). Strabismus was the leading symptom for 33 (25.4%) children, in whom the mean diagnostic delay was 2.9±0.7 months (median 31 days; interquartile range 10 to 121 days; range 0-18 months). As shown in Fig 2, presence of poor vision and eye inflammation predicted a late diagnosis of the tumor.

Taking the whole study population, Fig. 3 shows the association of the length of diagnostic delay and clinical finding of the tumor. It can be seen that extra ocular location of bilateral retinoblastoma was found in children with a diagnostic delay of 10 to 15 months, while extra ocular location with unilateral retinoblastoma was distinguished with a diagnostic delay of more than 15 months.

Stratifying the whole study population into patients with unilateral retinoblastoma (n=93, 59.2%) and patients with bilateral retinoblastoma (n=64, 40.8%) revealed that age was significantly (P<0.001) lower in the subgroup with bilateral retinoblastomas than in the subgroup with unilateral retinoblastomas (0.6±0.12 years; median 0.1 year; interquartile range 0-1 year; range 0-5 years vs 1.6±0.15 years; median 1.5 years; interquartile range 0-3 years; range 0-6 years).

The delay in the diagnosis of the tumor did not vary significantly between the subgroup with unilateral retinoblastomas (mean 3.9±0.87 months; median 1 month; interquartile range 7.2-91.7 days; range 0-36.5 months), and the
Consequences of Delayed Diagnosis in Treatment of Retinoblastoma

The clinical patterns of retinoblastoma

The mean age of patients was 1.21±0.11 years (59.2% unilateral), was consistent with the literature. Approximately 80% of patients are diagnosed when <4 years old[14]; 60% of cases represent as unilateral and the remaining bilateral[1,2].

Retrospective analysis of 157 cases of retinoblastoma between age and laterality pattern at the time of diagnosis revealed that bilateral retinoblastoma presents at an earlier age than unilateral retinoblastoma. This finding supports the Knudson "two-hit" hypothesis of retinoblastoma genetics[16].

The key point in the early diagnosis of retinoblastoma is referring to pediatricians who can detect ocular disorders, which parents do not perceive most times. Distinguishing the signs and symptoms, funduscopic screening and initiation of therapy as soon as possible are of paramount importance[14].

Ophthalmic disorders can present as strabismus and leukocoria[14]. Studies conducted in USA, UK, Brazil and China state that leukocoria is the most frequent symptom[3,14]. This was found in 67.51% of cases in our series, followed by strabismus (25.4%) and eye inflammation (7%). Literature reviews demonstrated that 50-60% of cases were diagnosed by leukocoria, 25% by strabismus and 6-10% by inflammation[14]. Bai and coworkers found the most frequent symptoms were leukocoria and poor vision, in addition to presence of strabismus related to late diagnosis of the tumor[3].

The mean delay in the diagnosis of retinoblastomas in Iranian children treated in the MPCTRC was 3.4±0.53 months. Duration of symptoms for longer than 10 months in enrolled patients was a prognostic factor for poor outcome. Rodriguez-Gallindo by reviewing cases of retinoblastoma at Brazil in 1995 demonstrated that 68% of patients showed a delay in diagnosis shorter than six months[7]. Bai and Rodrigues by different screening showed that delay diagnosis in their cases was 4.1 and 8.3 months respectively in China (2011) and Brazil (2004) [3,14]. In our study, the risk of delayed diagnosis was the same in both groups of patients with strabismus (2.9±0.7 months) and leukocoria (3.4±0.58 months), while Rodrigues et al found that cases with strabismus showed higher risk of delayed diagnosis (8.8 months).
months) than cases with leukocoria (5.6 months) [14].

The diagnostic delay was significantly longer in the age group > 4 years old than other age groups (P<0.05). While Bai et al showed this relation in the age group of 2-4 years.

There was a predominance of patients with intraocular tumor, which shows shorter duration of symptoms compared to those with advanced extra ocular tumors. Rodrigues et al reported improvement of prognosis in patients with intraocular retinoblastomas [14]. This improvement can be due to focusing on early recognition of retinoblastoma by public awareness. In our study, the patients with extra-ocular tumor exhibited signs for over 10 months, and both parents and ophthalmologists failed to make an early diagnosis. Patients with low educational level living in the rural and countryside showed advanced disease. Thus, the influence of educational awareness on parents and health services can lead to overcome delayed diagnoses.

Conclusion

According to these facts, for an infant/child with positive family history of retinoblastoma, early referring to ophthalmologist and pediatric oncologist is recommended. In addition, educational programs should be offered to bring into public awareness symptoms of retinoblastoma such as leukocoria, strabismus and eye inflammation to result in early diagnosis. Early diagnosis of retinoblastoma can be the critical risk factor in managing the patients as delay in diagnosis accounts for highly advanced tumor and poor prognosis.

Acknowledgment

The authors thank ophthalmologists who cared for enrolled patients. Research department thanks staff of medical archive in MPCTRC.

Authors’ Contribution

Concept / Design: M. Mehrvar, M. Alebouyeh, M. Tashvighi

Data selection, Clinical examination and treatment of patients: M. Faranoush, A.A. Hedayati Asl, A. Alebouyeh, M. Tashvighi

Data collection: R. Zangooei

Data analysis; E. Abadi, N. Mehrvar

Manuscript Preparation: N. Mehrvar, M. Faranoush

Critical Revision of the Manuscript: A. Mehrvar, M. Alebouyeh

All authors approved the final version of the paper.

Conflict of Interest: None

References

1. Abramson DH. Retinoblastoma in the 20th century: past success and future challenges. Weisfenfeld Lecture. Invest Ophthalmol Vis Sci 2005; 46(8): 2683-91.
2. Abramson DH, Schiffer AC. Update on retinoblastoma. Retina 2004; 24(6):828-48.
3. Bai S, Ren R, Li B, et al. Delay in the diagnosis of retinoblastoma in China. Acta Ophthalmol 2011; 89(1):72-4.
4. Al-Mester S. International Classification and management of retinoblastoma. Saudi J Ophthalmol 2006; 20(3):161-2.
5. Kaufman P, Paysse EA. Overview of retinoblastoma. Up To Date 2013 May-Dec.

6. Broaddus E, Topham A, Singh AD. Incidence of retinoblastoma in the United States: 1975-2004. Br J Ophthalmol 2009; 93(1):24-7.
7. Rodriguez-Gallindo C, Wilson M W, Chantada G, et al. Retinoblastoma: one world, one vision. Pediatrics 2008; 122(3):e763-70.
8. Chintagumpala M, Chevez-Barrios P, Paysse EA, et al. Retinoblastoma: review of current management. Oncologist 2007; 12(10):1237-46.
9. Butros LJ, Abramson DH, Dunkel IJ. Delayed diagnosis of retinoblastoma: analysis of degree, cause, and potential consequences. Pediatrics 2002; 109(3):E 45.
10. Canturk S, Qaddoumi I, Khaten V, et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health related indicators. Br J Ophthalmol 2010; 94(11):1432-6.
11. Goddard AG, Kingstone JE, Hungerford JL. Delay in diagnosis of retinoblastoma: risk factors and treatment outcome. Br J Ophthalmol 1999; 83(12): 1320-3.
12. Araki Y, Matsuyama Y, Kobayashi Y, et al. Secondary Neoplasms after retinoblastoma treatment: retrospective cohort study of 754 patients in Japan. Jpn J Clin Oncol 2011; 41(3):373-9.
13. Palamar M, Thangappan A, Shields CL. Evolution in regression patterns following chemoreduction for retinoblastoma. *Arch Ophtalmol* 2011; 129(6):727-30.

14. Rodrigues KES, Latorre RDO, de Camargo B. Delayed diagnosis in retinoblastoma. *J Pediatr (Rio J)* 2004;80(6):511-6.

15. Naseripour M, Nazari H, Bakhtiari P, et al. Retinoblastoma in Iran: outcomes in terms of patients’ survival and globe survival. *Br J Ophtalmol* 2009; 93(1):28-32.

16. Friedman DL. Retinoblastoma. In: Lanzkowsky PH. Manual of Pediatric Hematology and Oncology. 5th ed. London: Elsevier 2011; pp 759-775.

17. Zhao J, Li S, Shi J, Wang N. Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China. *Br J Ophtalmol* 2011; 95(10):1372-5.